News | August 01, 2024
Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Imfinzi also recommended for patients with mismatch repair deficient disease
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Subscribe To Our Newsletter & Stay Updated
